Cancer, Gastrointestinal stromal tumors, Gastroesophageal junction tumors, Gastroesophageal adenocarcinomas
RCUSArcus BiosciencesCatalyst overview
Research summary
This catalyst tracks a Failed discontinued for Domvanalimab + Zimberelimab + Chemo v.s. Nivolumab + Chemo in Cancer, Gastrointestinal stromal tumors, Gastroesophageal junction tumors, Gastroesophageal adenocarcinomas. The expected timing is based on the latest available company guidance and may change.
STAR-221 trial. Collab w/ GILD. 6/10/24- Complete Ph3 enrollment. 2/25/25- First data readout in 2026. 10/28/25:- EDGE-Gastric OS data support regimen; STAR-221 Phase 3 readout reiterated for 2026. 12/12/25:- STAR-221 Phase 3 gastric and esophageal study discontinued for futility at interim OS analysis.
Verification
Confirm timing and program details against the company announcement or filing.